Karyopharm Therapeutic Common Shares To Be Suspended, Effective Nov. 11; To Trade On OTC Under KPTIQ Ticker
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
Karyopharm, deep in debt, to sell itself in bankruptcy
Karyopharm Therapeutics Files for Chapter 11 Bankruptcy and Agrees to Planned Merger with Ayrmid
Rodman & Renshaw Downgrades Karyopharm Therapeutics to Neutral
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
Karyopharm Therapeutics Enters Restructuring Agreement With Lenders, Clearing Path For A Merger With Ayrmid; Secures Commitments For Up To $55M Of Debtor-In-Possession Financing
Karyopharm Therapeutics Extends Forbearance Period End Date To November 1, 2026
Karyopharm Therapeutics Extends Forbearance Period To October 15
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Signs Forbearance Agreement, Limited Waiver To Indentures For Additional Time To Advance Its Myelofibrosis Program; Did Not Pay $15.8M Due Under Sept. 10 Credit Agreement
Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
Karyopharm Therapeutics Submits sNDA To FDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib For Patients With Myelofibrosis
Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...
Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.